- Home
- NGNE vs OIA Comparison
NGNE vs OIA Comparison
Compare NGNE & OIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OIA
- Stock Information
- Founded
- NGNE 2003
- OIA 1988
- Country
- NGNE United States
- OIA United States
- Employees
- NGNE N/A
- OIA N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OIA Finance Companies
- Sector
- NGNE Health Care
- OIA Finance
- Exchange
- NGNE Nasdaq
- OIA Nasdaq
- Market Cap
- NGNE 325.3M
- OIA 267.0M
- IPO Year
- NGNE N/A
- OIA N/A
- Fundamental
- Price
- NGNE $19.95
- OIA $5.94
- Analyst Decision
- NGNE Strong Buy
- OIA
- Analyst Count
- NGNE 7
- OIA 0
- Target Price
- NGNE $41.86
- OIA N/A
- AVG Volume (30 Days)
- NGNE 113.3K
- OIA 97.9K
- Earning Date
- NGNE 08-11-2025
- OIA 01-01-0001
- Dividend Yield
- NGNE N/A
- OIA 4.88%
- EPS Growth
- NGNE N/A
- OIA N/A
- EPS
- NGNE N/A
- OIA N/A
- Revenue
- NGNE N/A
- OIA N/A
- Revenue This Year
- NGNE N/A
- OIA N/A
- Revenue Next Year
- NGNE N/A
- OIA N/A
- P/E Ratio
- NGNE N/A
- OIA N/A
- Revenue Growth
- NGNE N/A
- OIA N/A
- 52 Week Low
- NGNE $6.88
- OIA $4.93
- 52 Week High
- NGNE $74.49
- OIA $6.72
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- OIA 70.74
- Support Level
- NGNE $18.00
- OIA $5.66
- Resistance Level
- NGNE $19.93
- OIA $5.77
- Average True Range (ATR)
- NGNE 1.03
- OIA 0.07
- MACD
- NGNE 0.01
- OIA 0.03
- Stochastic Oscillator
- NGNE 55.71
- OIA 97.73
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.